Hansoh Pharma Reports Strong Phase II Results for Resencatinib in RET-Fusion NSCLC
I'm PortAI, I can summarize articles.
Hansoh Pharmaceutical Group Co. Ltd. announced strong Phase II results for resencatinib, a RET inhibitor, in treating RET-fusion NSCLC. The trial showed an 80% ORR in previously treated patients and 83.3% in treatment-naive patients, with a DCR of 96% and 93.3%, respectively. The 12-month progression-free survival rates were 81.1% and 79.3%. Resencatinib was well-tolerated with a manageable safety profile. The results were presented at the ESMO ASIA Congress 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments